102 results on '"Ma, Xiaosu"'
Search Results
2. Rethinking public service facility distribution and management strategies with the consideration of carbon peak – Insights from Suzhou, China
3. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
4. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
5. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
6. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
7. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
8. 336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
9. On joint railway and housing development strategy
10. Modeling transport management and land use over time
11. Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes.
12. Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes
13. 重庆直辖以来乡村人居环境可持续发展力及其时空分异研究
14. Generating and Visualizing Spatially Disaggregated Synthetic Population Using a Web-Based Geospatial Service
15. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements
16. Location of circular retro-reflective target based on micro-vision
17. 农户行为视角下的乡村生产空间系统运行机制及重构启示
18. Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis
19. Location of circular retro-reflective target based on micro-vision
20. Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus
21. Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus
22. The Effect of Age on Insulin Sensitivity and Insulin Secretion in First-Degree Relatives of Type 1 Diabetic Patients: A Population Analysis
23. Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis.
24. 20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies
25. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion vs. Subcutaneous Injection in Adults with Type 2 Diabetes and High Insulin Requirements
26. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus
27. Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus.
28. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements
29. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus
30. Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications
31. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)
32. Location of circular retro-reflective target based on micro-vision
33. 136 - Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion vs. Subcutaneous Injection in Adults with Type 2 Diabetes and High Insulin Requirements
34. Optimized Human Regular U-500 Insulin Treatment Improves β-Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes and High Insulin Requirements
35. Abstract #1215: Human Regular U-500 Insulin Treatment Over 24 Weeks Improves B-Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes: A Substudy of A Randomized, Titrationto-Target Clinical Trial
36. Abstract #269: Pharmacokinetic Bioequivalent and Non-Bioequivalent Concentrated Insulin Formulations: Implications for Clinical use and Dosing
37. Adaptive Transport Supply and Demand Management Strategies in an Integrated Land Use and Transport Model
38. Development of SFM of probing sensor look-alike
39. Application of PK/PD Modeling and Simulation to Dosing Regimen Optimization of High-Dose Human Regular U-500 Insulin
40. On Joint Railway and Housing Development Strategy
41. Long-term planning strategies for an integrated land use and transport system
42. 53: Are we guessing glyburide dosage in the treatment of gestational diabetes (GDM)? The pharmacological evidence for better clinical practice
43. Improvement to large-capacity pattern recognition using speckle modulation and suitable time schedule
44. Exposure-schedule study of uniform diffraction efficiency for DSSM holographic storage
45. Maximum and uniform diffraction efficiency of the multiple-volume holographic gratings in the spectrometer
46. Adaptive Transport Supply and Demand Management Strategies in an Integrated Land Use and Transport Model
47. Imaging spectral device based on multiple volume holographic gratings
48. Transport Management and Land Value
49. SOLBINSIRAN, A GALNAC-CONJUGATED SIRNA TARGETING ANGPTL3, REDUCES ATHEROGENIC LIPOPROTEINS IN INDIVIDUALS WITH MIXED DYSLIPIDAEMIA IN A DURABLE AND DOSEDEPENDENT MANNER.
50. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.